The application of inductively coupled plasma mass spectrometry in clinical pharmacological oncology research

Mass Spectrom Rev. 2008 Mar-Apr;27(2):67-100. doi: 10.1002/mas.20159.

Abstract

Metal-based anticancer agents are frequently used in the treatment of a wide variety of cancer types. The monitoring of these anticancer agents in biological samples is important to understand their pharmacokinetics, pharmacodynamics, and metabolism. In addition, determination of metals originating from anticancer agents is relevant to assess occupational exposure of health care personnel working with these drugs. The high sensitivity of inductively coupled plasma mass spectrometry (ICP-MS) has resulted in an increased popularity of this technique for the analysis of metal-based anticancer drugs. In addition to the quantitative analysis of the metal of interest in a sample, ICP-MS can be used as an ultrasensitive metal selective detector in combination with speciation techniques such as liquid chromatography. In the current review we provide a systematic survey of publications describing the analysis of platinum- and ruthenium-containing anticancer agents using ICP-MS, focused on the determination of total metal concentrations and on the speciation of metal compounds in biological fluids, DNA- and protein-adducts, and environmental samples. We conclude that ICP-MS is a powerful tool for the quantitative analysis of metal-based anticancer agents from multiple sample sources.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / analysis*
  • Antineoplastic Agents / pharmacokinetics
  • Biomedical Research*
  • Humans
  • Organoplatinum Compounds / analysis*
  • Organoplatinum Compounds / pharmacokinetics
  • Platinum / analysis
  • Ruthenium / analysis
  • Spectrophotometry, Atomic

Substances

  • Antineoplastic Agents
  • Organoplatinum Compounds
  • Platinum
  • Ruthenium